These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 29454659)
21. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549 [TBL] [Abstract][Full Text] [Related]
22. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study. Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465 [TBL] [Abstract][Full Text] [Related]
23. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593 [TBL] [Abstract][Full Text] [Related]
24. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG; Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282 [TBL] [Abstract][Full Text] [Related]
25. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. Rahimy E; Ying GS; Pan W; Hsu J Retina; 2019 Apr; 39(4):636-647. PubMed ID: 29517580 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial. Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R; JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148 [TBL] [Abstract][Full Text] [Related]
27. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524 [TBL] [Abstract][Full Text] [Related]
28. Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project. Daien V; Nguyen V; Morlet N; Arnold JJ; Essex RW; Young S; Hunyor A; Gillies MC; Barthelmes D; Am J Ophthalmol; 2018 Jun; 190():50-57. PubMed ID: 29550186 [TBL] [Abstract][Full Text] [Related]
29. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Brown DM; Chen E; Mariani A; Major JC; Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717 [TBL] [Abstract][Full Text] [Related]
30. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617 [TBL] [Abstract][Full Text] [Related]
31. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692 [TBL] [Abstract][Full Text] [Related]
32. Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis. Zarbin M; Tsuboi M; Hill LF; Stoilov I Ophthalmology; 2019 Jun; 126(6):849-855. PubMed ID: 30641096 [TBL] [Abstract][Full Text] [Related]
33. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies. Steinle NC; Du W; Gibson A; Saroj N Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314 [TBL] [Abstract][Full Text] [Related]
34. Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. Nguyen V; Vaze A; Fraser-Bell S; Arnold J; Essex RW; Barthelmes D; Gillies MC; Ophthalmol Retina; 2019 Aug; 3(8):623-628. PubMed ID: 31281103 [TBL] [Abstract][Full Text] [Related]